trending Market Intelligence /marketintelligence/en/news-insights/trending/-Zw1W8uC8rQt_X5aFwpnPA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

BioMarin gets $15M milestone payment from Pfizer after Talzenna's FDA approval

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


BioMarin gets $15M milestone payment from Pfizer after Talzenna's FDA approval

BioMarin Pharmaceutical Inc. received a $15 million milestone payment from Pfizer Inc. after the U.S. Food and Drug Administration approved Talzenna to treat a subtype of breast cancer.

Talzenna, or talazoparib, was approved to treat breast cancer with inherited BRCA-mutation, which does not express a large amount of a protein called HER2. Cancer cells without HER2, which helps to control cell growth, may grow more slowly and are less likely to recur compared to HER2-positive cancer.

California-based BioMarin sold Medivation Inc. all worldwide rights to Talzenna for an up-front payment of $410 million in August 2015. The agreement included up to $160 million in additional milestone payments, of which $35 million have been received by BioMarin.

In September 2016, Pfizer acquired Medivation and became responsible for research, development, regulatory and commercialization activities for Talzenna.